Humacyte (HUMA)
NASDAQ:HUMA
HUMA Stock Chart & Stats
$0.64
-$0.19(-4.01%)
At close: 4:00 PM EST
$0.64
-$0.19(-4.01%)
Day’s Range― - ―
52-Week Range$0.55 - $2.93
Previous CloseN/A
Volume1.64M
Average Volume (3M)8.08M
Market Cap
$143.29M
Enterprise Value$115.53M
Total Cash (Recent Filing)$50.50M
Total Debt (Recent Filing)$64.85M
Price to Earnings (P/E)―
Beta2.61
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding222,019,100
10 Day Avg. Volume5,781,063
30 Day Avg. Volume8,075,449
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)48.86
Price to Sales (P/S)74.54
P/FCF Ratio-1.43
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue56.69
Enterprise Value/Gross Profit-7.70
Enterprise Value/Ebitda-1.15
Forecast
1Y Price Target
$2.25Price Target Upside251.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$13.32M
Bulls Say, Bears Say
Bulls Say
Clinical Trial OutcomesAn interim analysis from a late-stage dialysis trial could support a regulatory filing for Symvess and materially expand addressable dialysis market opportunity if results meet endpoints.
Commercial Adoption And Pricing StrategyLowering average selling price alongside a new pricing scheme, cost-effectiveness studies, and progressing hospital purchasing approvals is increasing institutional uptake and could accelerate commercial traction.
Institutional And Military ProcurementInclusion of Symvess on the military electronic purchasing catalog combined with supportive appropriations creates a clear pathway for evaluation and procurement by military treatment facilities and VA hospitals, broadening potential sales channels.
Bears Say
Cash Burn And Funding RunwayHigh cash burn tied to the early launch and ongoing development programs is creating funding pressure that could necessitate further dilutive financing if revenue growth does not accelerate.
Financing And Shareholder DilutionAdditional financing raised at a discounted price and replacement of prior financing arrangements increased share count, producing dilution that may constrain near-term share-price appreciation.
Weak Sales PerformanceReported product sales and early U.S. launch results were substantially below expectations, highlighting early commercialization challenges that could pressure near-term performance.
Humacyte News
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $0.55 and its highest was $2.93 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $143.29M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is May 08, 2026 which is in 25 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on Mar 27, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.132 by $0.002.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Humacyte have?
Humacyte has 222,019,100 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.132. Following the earnings report the stock price went down -13.239%.
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Humacyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.25 (251.56% Upside)
$2.25 (251.56% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 52.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.91%
12-Months-Change
Fundamentals
Return on Equity
-424.76%
Trailing 12-Months
Asset Growth
-15.60%
Trailing 12-Months
Company Description
Humacyte
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
HUMA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several positive developments, including a significant increase in product sales, expansion of hospital approvals, positive long-term results for Symvess, a strong financial performance with reduced net loss, successful fundraising, and expansion of intellectual property. However, challenges remain with increased administrative expenses and some resistance in the hospital VAC process due to budget constraints.View all HUMA earnings summariesHUMA Stock 12 Month Forecast
Average Price Target
$2.25
▲(251.56% Upside)
Technical Analysis
Cartesian Therapeutics
―
Allogene Therapeutics
―
―
Foghorn Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
11.39% Insiders
5.88% Mutual Funds
2.56% Other Institutional Investors
71.53% Public Companies and
Individual Investors